Latest News and Press Releases

GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune...

Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to...

Tumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naïve CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in...

AIM technology represents a scalable therapeutic platform that has the potential to create new, multi-antigen specific therapies for virally driven infectious diseases, cancers and autoimmune diseases...

Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate...

GAITHERSBURG, Md., Oct. 06, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...

Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related...

First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product...

Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND) submission for NEXI-003, the Company’s first product...